Download PDF
TumorDiagnostik & Therapie 2018; 39(02): 105-109
DOI: 10.1055/s-0044-100836
Schwerpunkt Melanome
© Georg Thieme Verlag KG Stuttgart · New York

Systemtherapie des fortgeschrittenen metastasierten Melanoms

Johannes Kleemann
,
Markus Meissner
Further Information

Publication History

Publication Date:
02 March 2018 (online)

Also available at
    Permissions and Reprints

Für die Therapie des fortgeschrittenen malignen Melanoms wurden in den letzten Jahren zahlreiche neue Substanzen zugelassen, die erstmalig das Gesamtüberleben von Patienten positiv beeinflussen können. Dieser Beitrag fasst den aktuellen klinischen Stand der modernen Melanomtherapie zusammen und gibt einen Ausblick auf Entwicklungen in der adjuvanten Therapie.
 

  • Literatur

  • 2 Hodi FS, O’Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
    CrossrefPubMedGoogle Scholar
  • 3 Maio M, Grob JJ, Aamdal S. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015; 33: 1191-1196
    CrossrefPubMedGoogle Scholar
  • 4 Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007; 13: 5238-5242
    CrossrefPubMedGoogle Scholar
  • 5 Merelli B, Massi D, Cattaneo L. et al. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014; 89: 140-165
    CrossrefPubMedGoogle Scholar
  • 6 Obeid JM, Erdag G, Smolkin ME. et al. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunol 2016; 5: e1235107
    PubMedGoogle Scholar
  • 7 Robert C, Long GV, Brady B. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
    CrossrefPubMedGoogle Scholar
  • 8 Hodi FS, Kluger H, Sznol M. et al. Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Cancer Res 2016 76. Abstr. CT001
    PubMedGoogle Scholar
  • 9 Robert C, Schachter J, Long GV. et al. Pembrolizumab vs. Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372: 2521-2532
    CrossrefPubMedGoogle Scholar
  • 10 Schachter J, Ribas A, Long GV. et al. Pembrolizumab vs. ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390: 1853-1862
    CrossrefPubMedGoogle Scholar
  • 11 Robert C, Ribas A, Hamid O. et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 2016; 34: 9503-9503
    CrossrefPubMedGoogle Scholar
  • 12 Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23-34
    CrossrefPubMedGoogle Scholar
  • 13 Wolchok JD, Chiarion-Sileni V, Gonzalez R. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377: 1345-1356
    CrossrefPubMedGoogle Scholar
  • 14 Tawbi H, Forsyth P, Algazi A. et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. J Clin Oncol 2017; 35: 9507-9507
    CrossrefPubMedGoogle Scholar
  • 15 Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011; 9: 277-286
    PubMedGoogle Scholar
  • 16 Davies H, Bignell GR, Cox C. et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
    CrossrefPubMedGoogle Scholar
  • 17 Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell 2015; 161: 1681-1696
    CrossrefPubMedGoogle Scholar
  • 18 Chapman PB, Hauschild A, Robert C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516
    CrossrefPubMedGoogle Scholar
  • 19 McArthur GA, Chapman PB, Robert C. et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332
    CrossrefPubMedGoogle Scholar
  • 20 Hauschild A, Grob JJ, Demidov LV. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
    CrossrefPubMedGoogle Scholar
  • 21 Hauschild A, Grobb J, Demidov L. et al. 1092PD An Update on Overall Survival (Os) and Follow-on Therapies in Break-3, a Phase Iii, Randomized Trial: Dabrafenib (D) Vs. Dacarbazine (Dtic) in Patients (Pts) with Braf V600e Mutation-Positive Metastatic Melanoma (Mm). Ann Oncol 2014; 25: iv378-iv378
    PubMedGoogle Scholar
  • 22 Gibney GT, Messina JL, Fedorenko IV. et al. Paradoxical oncogenesis – the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013; 10: 390-399
    CrossrefPubMedGoogle Scholar
  • 23 Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014; 5: 10206-10221
    CrossrefPubMedGoogle Scholar
  • 24 Ascierto PA, McArthur GA, Dréno B. et al. Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; 17: 1248-1260
    CrossrefPubMedGoogle Scholar
  • 25 Long GV, Flaherty KT, Stroyakovskiy D. et al. Dabrafenib plus trametinib vs. dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017; 28: 1631-1639
    CrossrefPubMedGoogle Scholar
  • 26 Davies MA, Saiag P, Robert C. et al. Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017; 18: 863-873
    CrossrefPubMedGoogle Scholar
  • 27 Harrington KJ, Puzanov I, Hecht JR. et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther 2015; 15: 1389-1403
    CrossrefPubMedGoogle Scholar
  • 28 Liu BL, Robinson M, Han ZQ. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292-303
    CrossrefPubMedGoogle Scholar
  • 29 Andtbacka RH, Kaufman HL, Collichio F. et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 2015; 33: 2780-2788
    CrossrefPubMedGoogle Scholar
  • 30 Harrington KJ, Andtbacka RH, Collichio F. et al. Efficacy and safety of talimogene laherparepvec vs. granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther 2016; 9: 7081-7093
    CrossrefPubMedGoogle Scholar
  • 31 Chesney J, Puzanov I, Collichio F. et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Vs. Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 2017; DOI: 10.1200/JCO.2017.73.7379: JCO2017737379.
    CrossrefPubMedGoogle Scholar
  • 32 Long GV, Dummer R, Ribas A. et al. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). J Immun Therap Cancer 2015; 3: P181
    PubMedGoogle Scholar
  • 33 Ribas A, Dummer R, Puzanov I. et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell 2017; 170: 1109-1119
    CrossrefPubMedGoogle Scholar
  • 34 Ives NJ, Suciu S, Eggermont AMM. et al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer 2017; 82: 171-183
    CrossrefPubMedGoogle Scholar
  • 35 Eggermont AM, Chiarion-Sileni V, Grob JJ. et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016; 375: 1845-1855
    CrossrefPubMedGoogle Scholar
  • 36 Weber J, Mandala M, Del Vecchio M. et al. Adjuvant Nivolumab vs. Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377: 1824-1835
    CrossrefPubMedGoogle Scholar
  • 37 Long GV, Hauschild A, Santinami M. et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377: 1813-1823
    CrossrefPubMedGoogle Scholar